EGFR and pneumonitis: Sunvozertinib and zongertinib, for example, were associated with lower rates of dose-limiting pneumonitis compared with earlier EGFR inhibitors, but gastrointestinal side effects were relatively common, with grade ≥3 diarrhea observed in about 15-20 % of patients (Mina et al., 2025[83]; Sun et al., 2024[117]).